Telix Pharmaceuticals Director Maria Rivas Acquires 9,000 ADS on Nasdaq at US$9.034 Each

Mukul

05 November 2026 03:14 PM AEDT

Telix Pharmaceuticals Director Maria Rivas Acquires 9,000 ADS on Nasdaq at US$9.034 Each

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Telix Pharmaceuticals Limited (ASX:TLX) has disclosed that director Maria Rivas acquired 9,000 American Depositary Shares (ADS) on 30 October 2026 (US time) at a price of US$9.034 per ADS, according to a Change of Director's Interest Notice lodged with the exchange.

Key Points

Director Maria Rivas acquired 9,000 Telix ADS on Nasdaq (NASDAQ:TLX) on 30 October 2026 (US time) at US$9.034 per ADS.
The acquisition was an on-market trade conducted on Nasdaq; no securities were disposed of.
Following the change, Rivas holds 9,000 ADS and 21,597 Share Appreciation Rights (SARs), all in her name directly.
The transaction did not occur during a closed period requiring prior written clearance.

Details of the Nasdaq On-Market Trade

The filing states that Maria Rivas acquired 9,000 ADS at a consideration of US$9.034 per ADS through an on-market trade on Nasdaq. Each ADS represents one ordinary share in Telix Pharmaceuticals Limited. No securities were disposed of as part of this transaction. The interest is held directly in the name of Maria Rivas. The date of the previous director's interest notice for Rivas was recorded as 1 June 2026, with the current change occurring on 30 October 2026 (US time).

Director's Securities Holdings After Change

Following the transaction, Maria Rivas holds two classes of securities in Telix Pharmaceuticals. The filing discloses that she retains 21,597 Share Appreciation Rights (SARs) in her name, unchanged from the position prior to the acquisition. In addition, she now directly holds 9,000 ADS in her name. The nature of the interest is recorded as direct, and no indirect interests or interests in contracts were reported as part of this disclosure. Part 2 of the notice, relating to changes in director interests in contracts, returned not applicable across all fields.

Closed Period Confirmation

The filing confirms that the securities detailed in the notice were not traded during a closed period in which prior written clearance was required. As a result, the fields relating to whether prior written clearance was provided, and the date on which any such clearance was given, are recorded as not applicable. The disclosure was lodged by Telix Pharmaceuticals Limited, ABN 85 616 620 369, under ASX Listing Rule 3.19A.2 and as agent for the director under section 205G of the Corporations Act.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.